Exoxemis Exoxemis - Indications
Home Technology Indications Collaborations Company Publications Contact
Nosocosmial Infections Surgical Site Infection Biodefence
 
>

Nosocomial Infections

Multiple MPO formulations are in development for prevention of serious, and often resistant, hospital-acquired infections.
more >>

 
       
>

Surgical Site Infection Prevention

Our unique MPO formulation holds the promise of a breakthrough in surgical site infection prevention.

   
       
>

Biodefense

The MPO technology platform suggests the potential for use in preventing infections in conventional and biological attack situations.
more >>

   
       
>
E-mail Inquiries    

Surgical Site Infection Prevention

The unique myeloperoxidase formulation developed by Exoxemis holds the promise of a breakthrough in the field of surgical site infection prevention. Surgical site infection (SSI) is an important and persistent problem causing substantial morbidity, mortality, and cost.


Large potential market

With close to 40 million operations performed annually in the United States, the potential market for SSI prevention products is projected to reach several billion dollars. Strong, steady growth of this market is driven by increasing numbers of elderly, immunocompromised patients, high risk surgeries, drug resistant strains, outpatient surgeries, and shorter hospital stays. With antimicrobial resistance posing a growing threat, there are few, if any, locally administered alternatives for intra-operative prevention of SSI.

The Exoxemis MPO system addresses the clinical demand for new preventive and therapeutic approaches that effectively respond to the growing problem of surgical site infections. Our Surgical Site Infection Prevention formulation is expected to enter Phase I testing within a year and is currently available for licensing.